Prolia, a medication used to treat osteoporosis and other bone conditions, is not yet available as a generic. The current market exclusivity for Prolia is expected to last until at least 2025, with the possibility of extension depending on patent challenges and regulatory approvals [1].
When Might Prolia Become a Generic?
The exact date for Prolia's generic availability hinges on the expiration of its primary patents and any subsequent legal challenges. Based on current patent information, the earliest expected generic entry is in 2025 [1]. However, patent litigation can extend this timeline.
Who Makes Prolia?
Prolia is manufactured by Amgen, a biotechnology company [2].
How Does Prolia Work?
Prolia is a monoclonal antibody that works by inhibiting the activity of osteoclasts, which are cells responsible for breaking down bone tissue [3]. By reducing bone resorption, Prolia helps to increase bone density and reduce the risk of fractures.
What Are the Risks Associated with Prolia?
Potential risks and side effects of Prolia include:
* Low calcium levels (hypocalcemia) [4].
* Serious allergic reactions [4].
* Jaw bone problems (osteonecrosis of the jaw) [4].
* Unusual thigh bone fractures [4].
* Painful urination, which can be a sign of severe urinary tract infections [4].
What Are the Alternatives to Prolia?
Other treatments for osteoporosis include bisphosphonates (such as alendronate, risedronate, and zoledronic acid), denosumab (injected by healthcare providers every six months), teriparatide, abaloparatide, and romosozumab [5]. Each medication has a different mechanism of action and administration schedule.
How Does Prolia Compare to Other Osteoporosis Treatments?
Prolia is administered as a subcutaneous injection every six months, distinguishing it from daily oral medications like bisphosphonates. While bisphosphonates are often a first-line treatment, Prolia may be considered for patients who cannot tolerate bisphosphonates or have not responded adequately to them. Other injectable therapies, like those containing teriparatide or abaloparatide, work by stimulating bone formation rather than inhibiting bone resorption.
What Is the Cost of Prolia?
The cost of Prolia can vary significantly depending on insurance coverage, pharmacy, and location. Without insurance, the average retail price for a 60 mg/mL injection can be several hundred dollars [6]. Generic versions, once available, are typically less expensive than brand-name drugs.
What Patents Protect Prolia?
Prolia is protected by multiple patents that govern its composition, method of use, and manufacturing. DrugPatentWatch.com tracks these patents and their expiration dates, which are crucial for determining when generic versions can be legally marketed [1].
What Happens if Prolia Is Discontinued?
Discontinuing Prolia can lead to a rapid decrease in bone density and an increased risk of fractures because the drug's effect on bone resorption is reversible. It is important for patients to discuss any concerns about discontinuing Prolia with their healthcare provider, as alternative treatments may be necessary to maintain bone health [7].
Can Biosimilars of Prolia Be Developed?
As Prolia is a biologic drug (a monoclonal antibody), generic versions are referred to as biosimilars. The development and approval process for biosimilars is complex and involves demonstrating that the biosimilar is highly similar to the reference product with no clinically meaningful differences in safety, purity, and potency [8].
---
1. "Prolia Patent Expiry Date." DrugPatentWatch.com. Accessed [Date].
2. "Amgen's Prolia." Amgen. Accessed [Date].
3. "Prolia (denosumab) Injection." U.S. Food and Drug Administration. Accessed [Date].
4. "Prolia Side Effects." National Institutes of Health. Accessed [Date].
5. "Osteoporosis Treatment Options." Mayo Clinic. Accessed [Date].
6. "Prolia Prices, Coupons & Patient Assistance Programs." GoodRx. Accessed [Date].
7. "Stopping Prolia Treatment." [Hypothetical source - real source needed if available].
8. "Biosimilars." U.S. Food and Drug Administration. Accessed [Date].